Relmada Therapeutics (RLMD) Non-cash Items (2017 - 2026)

Relmada Therapeutics (RLMD) has 10 years of Non-cash Items data on file, last reported at $10.8 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $10.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $10.8 million (changed N/A YoY), and the FY2025 annual result was $6.9 million, down 57.55% from the prior year.
• Non-cash Items climbed to $10.8 million in Q1 2026 per RLMD's latest filing, from $6.9 million in the prior quarter.
• Over five years, Non-cash Items peaked at $32.0 million in Q3 2024 and troughed at $417998.0 in Q4 2022.
• A 5-year average of $9.6 million and a median of $8.0 million in 2022 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2022 and 2023: Non-cash Items tumbled 80.47% in 2022, then soared 2575.46% in 2023.
• A 5-year view of Non-cash Items shows it stood at $417998.0 in 2022, then soared by 2575.46% to $11.2 million in 2023, then surged by 45.65% to $16.3 million in 2024, then sank by 57.55% to $6.9 million in 2025, then jumped by 56.13% to $10.8 million in 2026.
• Business Quant data shows RLMD's Non-cash Items at $10.8 million in Q1 2026, $6.9 million in Q4 2025, and $9.7 million in Q3 2025.